Octave® Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate  Biomarker Test for Parkinson’s Disease. Learn More

Octave MSDA Test: Provider Guide for Biomarker Information

Octave MSDA Test: Provider Guide for Biomarker Information


1) Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246-257. doi:10.1016/S1474-4422(22)00009-6

2) Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis [published correction appears in Sci Rep. 2019 Jun 5;9(1):8433]. Sci Rep. 2018;8(1):14798. Published 2018 Oct 4.

3) Gatto M, Iaccarino L, Ghirardello A, et al. Serpins, immunity and autoimmunity: old molecules, new functions. Clin Rev Allergy Immunol. 2013;45(2):267-280.

4) Fang Y, Ma K, Huang YM, et al. Fibronectin leucine-rich transmembrane protein 2 drives monocyte differentiation into macrophages via the UNC5B-Akt/mTOR axis. Front Immunol. 2023;14:1162004. Published 2023 Apr 6.

5) van Nierop GP, Janssen M, Mitterreiter JG, et al. Intrathecal CD4(+) and CD8(+) T-cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients. Eur J Immunol. 2016;46(2):347-353.

6) Leshchyns’ka I, Sytnyk V. Reciprocal Interactions between Cell Adhesion Molecules of the Immunoglobulin Superfamily and the Cytoskeleton in Neurons. Front Cell Dev Biol. 2016;4:9. Published 2016 Feb 16.

7) Stampanoni Bassi M, Buttari F, Gilio L, et al. Osteopontin Is Associated with Multiple Sclerosis Relapses. Biomedicines. 2023;11(1):178. Published 2023 Jan 11.

8) Olsen JA, Kenna LA, Tipon RC, Spelios MG, Stecker MM, Akirav EM. A Minimally-invasive Blood-derived Biomarker of Oligodendrocyte Cell-loss in Multiple Sclerosis. EBioMedicine. 2016;10:227-235.

9) Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler. 2010;16(2):208-217.

10) Festa ED, Hankiewicz K, Kim S, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler. 2009;15(11):1271-1279.

11) Li Y, Singer NG, Whitbred J, Bowen MA, Fox DA, Lin F. CD6 as a potential target for treating multiple sclerosis. Proc Natl Acad Sci U S A. 2017;114(10):2687-2692.

12) Cui LY, Chu SF, Chen NH. The role of chemokines and chemokine receptors in multiple sclerosis. Int Immunopharmacol. 2020;83:106314.

13)  Matías-Guiu JA, Oreja-Guevara C, Cabrera-Martín MN, Moreno-Ramos T, Carreras JL, Matías-Guiu J. Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging. Front Neurol. 2016;7:53. Published 2016 Mar 31.

14) Glasnović A, O’Mara N, Kovačić N, et al. RANK/RANKL/OPG Signaling in the Brain: A Systematic Review of the Literature. Front Neurol. 2020 Nov 19;11:590480.

15) López-Gómez C, Fernández O, García-León JA, et al. TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis. PLoS One. 2011;6(7):e21766.

16)  Steri M, Orrù V, Idda ML, et al. Overexpression of the Cytokine BAFF and Autoimmunity Risk. N Engl J Med. 2017;376(17):1615-1626.

17) Varadé J, Comabella M, Ortiz MA, et al. Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes. Mult Scler. 2012;18(7):959-965.

18) Enyindah-Asonye G, Li Y, Ruth JH, et al. CD318 is a ligand for CD6. Proc Natl Acad Sci U S A. 2017;114(33):E6912-E6921.

[Additional references available upon request]